嘌呤-6-羧酸 | 2365-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 嘌呤-6-羧酸
• 英文名称: 7H-purine-6-carboxylic acid
• 英文别名: 1H-Purine-6-carboxylic acid
• CAS: 2365-43-7
• 化学式: C₆H₄N₄O₂
• mdl: MFCD06208344
• 分子量: 164.123
• InChiKey: CIEQXUBLKKQRIS-UHFFFAOYSA-N

物化性质

• 熔点：
  199℃ (decomposition)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  嘌呤-6-羧酸 生成 嘌呤
  参考文献：
  名称：

  Studies on Condensed Pyrimidine Systems. XVIII. Substances Related to 6-Purinecarboxylic Acid

  摘要：

  DOI：

  10.1021/ja01595a066
• 作为产物：
  描述：

  butyl 7H-purine-6-carboxylate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以200 mg的产率得到嘌呤-6-羧酸
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  化合物的化学式为(I)：其中每个符号如规范中所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症、阿尔茨海默病等疾病的预防或治疗药物。

  公开号：

  US20160159808A1

文献信息

• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof
  申请人：MAILLIET Patrick

  公开号：US20080153837A1

  公开（公告）日：2008-06-26

  This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

  这项发明涉及4-(苯并咪唑-2-基)芴和4-(氮杂苯并咪唑-2-基)芴的衍生物，涉及包含这些衍生物的药物组合物，以及涉及治疗与Hsp90蛋白活性相关的疾病的方法，包括给予这些衍生物。
• Heterobicyclic metalloprotease inhibitors
  申请人：Bluhm Harald

  公开号：US20080221092A1

  公开（公告）日：2008-09-11

  The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.

  本发明通常涉及含有酰胺的杂双环含有药物作用的化合物，特别地，涉及含有酰胺的杂双环金属蛋白酶抑制剂。更具体地，本发明提供了一类新型的杂双环MMP-3和/或MMP-13抑制剂化合物，相对于目前已知的MMP-13和MMP-3抑制剂，这些化合物表现出更高的效力和选择性。
• Porous polymer material for bonding metal-containing ions or for purifying organic molecules
  申请人：instrAction GmbH

  公开号：US11014071B1

  公开（公告）日：2021-05-25

  A method for producing porous particles of a cross-linked polymer, and porous particles that can be produced according to the method are disclosed. The porous particles of a crosslinked hydroxy- or amino-group-containing polymer have a relatively low swelling factor. A composite material contains the porous particles dispersed in a continuous aqueous phase. The porous particles, or the composite material, are used for purifying organic molecules and for bonding metals from solutions. A filter cartridge contains the porous particles of a cross-linked polymer or the composite material.

  本发明公开了一种生产交联聚合物多孔颗粒的方法，以及根据该方法生产的多孔颗粒。交联的含羟基或氨基聚合物的多孔颗粒具有相对较低的膨胀系数。复合材料包含分散在连续水相中的多孔颗粒。多孔颗粒或复合材料可用于从溶液中净化有机分子和粘合金属。滤芯含有交联聚合物多孔颗粒或复合材料。
• Immunostimulatory, Covalently lipidated oligonucleotides
  申请人：Jiang Zi-Hua

  公开号：US20060189550A1

  公开（公告）日：2006-08-24

  Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.

  包含 CpG 二核苷酸单元或其类似物的共价脂质化寡核苷酸可用作免疫刺激剂，单独或与免疫原和/或非免疫制剂一起使用，以防止由癌细胞或病原体引起的疾病。具有特殊骨架的脂质化寡核苷酸、核苷酸少于 8 个的脂质化寡核苷酸以及由多个含 CpG 二核苷酸的片段组成的脂质化寡核苷酸（这些片段通过长核苷酸间连接连接）尤其令人感兴趣。这些化合物本身也很新颖。